210 related articles for article (PubMed ID: 23183443)
1. Rifaximin resistance in Escherichia coli associated with inflammatory bowel disease correlates with prior rifaximin use, mutations in rpoB, and activity of Phe-Arg-β-naphthylamide-inhibitable efflux pumps.
Kothary V; Scherl EJ; Bosworth B; Jiang ZD; Dupont HL; Harel J; Simpson KW; Dogan B
Antimicrob Agents Chemother; 2013 Feb; 57(2):811-7. PubMed ID: 23183443
[TBL] [Abstract][Full Text] [Related]
2. Fitness and molecular mechanisms of resistance to rifaximin in in vitro selected Escherichia coli mutants.
Pons MJ; Mensa L; Gascón J; Ruiz J
Microb Drug Resist; 2012 Aug; 18(4):376-9. PubMed ID: 21711150
[TBL] [Abstract][Full Text] [Related]
3. Multidrug resistance is common in Escherichia coli associated with ileal Crohn's disease.
Dogan B; Scherl E; Bosworth B; Yantiss R; Altier C; McDonough PL; Jiang ZD; Dupont HL; Garneau P; Harel J; Rishniw M; Simpson KW
Inflamm Bowel Dis; 2013 Jan; 19(1):141-50. PubMed ID: 22508665
[TBL] [Abstract][Full Text] [Related]
4. Relevant role of efflux pumps in high levels of rifaximin resistance in Escherichia coli clinical isolates.
Gomes C; Ruiz L; Pons MJ; Ochoa TJ; Ruiz J
Trans R Soc Trop Med Hyg; 2013 Sep; 107(9):545-9. PubMed ID: 23843564
[TBL] [Abstract][Full Text] [Related]
5. Rifamycin inhibition of WT and Rif-resistant Mycobacterium tuberculosis and Escherichia coli RNA polymerases in vitro.
Gill SK; Garcia GA
Tuberculosis (Edinb); 2011 Sep; 91(5):361-9. PubMed ID: 21704562
[TBL] [Abstract][Full Text] [Related]
6. Microevolution in fimH gene of mucosa-associated Escherichia coli strains isolated from pediatric patients with inflammatory bowel disease.
Iebba V; Conte MP; Lepanto MS; Di Nardo G; Santangelo F; Aloi M; Totino V; Checchi MP; Longhi C; Cucchiara S; Schippa S
Infect Immun; 2012 Apr; 80(4):1408-17. PubMed ID: 22290143
[TBL] [Abstract][Full Text] [Related]
7. In vitro development and analysis of Escherichia coli and Shigella boydii azithromycin-resistant mutants.
Gomes C; Pons MJ; Magallon-Tejada A; Durand D; Lluque A; Mosquito S; Riveros M; Mercado E; Prada A; Ochoa TJ; Ruiz J
Microb Drug Resist; 2013 Apr; 19(2):88-93. PubMed ID: 23176550
[TBL] [Abstract][Full Text] [Related]
8. Development of Escherichia coli rifaximin-resistant mutants: frequency of selection and stability.
Ruiz J; Mensa L; Pons MJ; Vila J; Gascon J
J Antimicrob Chemother; 2008 May; 61(5):1016-9. PubMed ID: 18325895
[TBL] [Abstract][Full Text] [Related]
9. Rifaximin decreases virulence of Crohn's disease-associated Escherichia coli and epithelial inflammatory responses.
Dogan B; Fu J; Zhang S; Scherl EJ; Simpson KW
J Antibiot (Tokyo); 2018 May; 71(5):485-494. PubMed ID: 29410518
[TBL] [Abstract][Full Text] [Related]
10. Dominant genotypes in mucosa-associated Escherichia coli strains from pediatric patients with inflammatory bowel disease.
Schippa S; Conte MP; Borrelli O; Iebba V; Aleandri M; Seganti L; Longhi C; Chiarini F; Osborn J; Cucchiara S
Inflamm Bowel Dis; 2009 May; 15(5):661-72. PubMed ID: 19067417
[TBL] [Abstract][Full Text] [Related]
11. Rifampin and rifaximin resistance in clinical isolates of Clostridium difficile.
O'Connor JR; Galang MA; Sambol SP; Hecht DW; Vedantam G; Gerding DN; Johnson S
Antimicrob Agents Chemother; 2008 Aug; 52(8):2813-7. PubMed ID: 18559647
[TBL] [Abstract][Full Text] [Related]
12. Review article: the potential mechanisms of action of rifaximin in the management of inflammatory bowel diseases.
Sartor RB
Aliment Pharmacol Ther; 2016 Jan; 43 Suppl 1():27-36. PubMed ID: 26618923
[TBL] [Abstract][Full Text] [Related]
13. In vitro activity of rifaximin against clinical isolates of Escherichia coli and other enteropathogenic bacteria isolated from travellers returning to the UK.
Hopkins KL; Mushtaq S; Richardson JF; Doumith M; de Pinna E; Cheasty T; Wain J; Livermore DM; Woodford N
Int J Antimicrob Agents; 2014 May; 43(5):431-7. PubMed ID: 24661532
[TBL] [Abstract][Full Text] [Related]
14. Culture independent analysis of ileal mucosa reveals a selective increase in invasive Escherichia coli of novel phylogeny relative to depletion of Clostridiales in Crohn's disease involving the ileum.
Baumgart M; Dogan B; Rishniw M; Weitzman G; Bosworth B; Yantiss R; Orsi RH; Wiedmann M; McDonough P; Kim SG; Berg D; Schukken Y; Scherl E; Simpson KW
ISME J; 2007 Sep; 1(5):403-18. PubMed ID: 18043660
[TBL] [Abstract][Full Text] [Related]
15. High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn's disease.
Darfeuille-Michaud A; Boudeau J; Bulois P; Neut C; Glasser AL; Barnich N; Bringer MA; Swidsinski A; Beaugerie L; Colombel JF
Gastroenterology; 2004 Aug; 127(2):412-21. PubMed ID: 15300573
[TBL] [Abstract][Full Text] [Related]
16. High prevalence of aggregative adherent Escherichia coli strains in the mucosa-associated microbiota of patients with inflammatory bowel diseases.
Thomazini CM; Samegima DA; Rodrigues MA; Victoria CR; Rodrigues J
Int J Med Microbiol; 2011 Aug; 301(6):475-9. PubMed ID: 21616711
[TBL] [Abstract][Full Text] [Related]
17. [Presence of intracellular Escherichia coli in patients with inflammatory bowel disease].
De La Fuente M; Chahuán I; Gutiérrez R; Díaz-Jiménez D; Olivares M; Vidal R; Simian D; Figueroa C; Quera R; Hermoso MA
Rev Med Chil; 2017 Sep; 145(9):1129-1136. PubMed ID: 29424399
[TBL] [Abstract][Full Text] [Related]
18. High-resolution melting analysis of the single nucleotide polymorphism hot-spot region in the rpoB gene as an indicator of reduced susceptibility to rifaximin in Clostridium difficile.
Pecavar V; Blaschitz M; Hufnagl P; Zeinzinger J; Fiedler A; Allerberger F; Maass M; Indra A
J Med Microbiol; 2012 Jun; 61(Pt 6):780-785. PubMed ID: 22361457
[TBL] [Abstract][Full Text] [Related]
19. Effect of 1-(1-naphthylmethyl)-piperazine, a novel putative efflux pump inhibitor, on antimicrobial drug susceptibility in clinical isolates of Escherichia coli.
Kern WV; Steinke P; Schumacher A; Schuster S; von Baum H; Bohnert JA
J Antimicrob Chemother; 2006 Feb; 57(2):339-43. PubMed ID: 16354747
[TBL] [Abstract][Full Text] [Related]
20. The prevalence of mucosa-associated diffusely adherent Escherichia coli in children with inflammatory bowel disease.
Walczuk U; Sobieszczańska B; Turniak M; Rzeszutko M; Duda-Madej A; Iwańczak B
Adv Clin Exp Med; 2019 Jul; 28(7):899-905. PubMed ID: 31066244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
